Publication:
Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey

dc.contributor.coauthorİnan, Berin
dc.contributor.coauthorGöçmen, Rahşan
dc.contributor.coauthorÇolpak, Ayşe İlksen
dc.contributor.coauthorMeinl, Edgar
dc.contributor.coauthorKarabudak, Rana
dc.contributor.coauthorTuncer, Aslı
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.facultymemberYes
dc.contributor.kuauthorVural, Atay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteResearch Center
dc.date.accessioned2024-11-09T23:36:46Z
dc.date.issued2020
dc.description.abstractBackground: To identify the clinical and radiological characteristics of adult patients with myelin oligodendrocyte glycoprotein antibody disease (MOG-AD) in a Turkish cohort. Methods: Clinical and radiological data were obtained retrospectively. Serological testing was done with fixed and live cell-based assays. Results: Optic neuritis was the most common presenting symptom, and neuromyelitis optica spectrum disorder (NMOSD) without aquaporin-4 antibody (AQP4-IgG) was the most common phenotype. Most patients had a relapsing course. Steroid dependency was common. Conus involvement was a frequent clinical and radiological feature. Radiological features such as long segment involvement and perineural optic nerve gadolinium enhancement were also typical in our cohort. One patient presented with encephalopathy and seizures, pointing out to the importance of testing of myelin oligodendrocyte antibody (MOG-IgG) in such patients as well. Conclusion: Myelin oligodendrocyte glycoprotein antibody disease is a heterogeneous clinical entity with characteristic clinical and radiological features. Our single-center experience underlines prominent clinical and magnetic resonance imaging (MRI) features and provides our treatment experiences.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipScientific and Technological Research Council of Türkiye (TÜBİTAK) [118S397]
dc.description.sponsorshipGerman Research Foundation (DFG) [SFB TR128]
dc.description.sponsorshipEuropean Academy of Neurology Research Fellowship
dc.description.sponsorshipAlexander von Humboldt Foundation
dc.description.studentonlypublicationNo
dc.description.studentpublicationNo
dc.description.versionN/A
dc.identifier.WoSQuartileQ2
dc.identifier.doi10.1016/j.msard.2020.102376
dc.identifier.eissn2211-0356
dc.identifier.embargoN/A
dc.identifier.grantno118S397
dc.identifier.grantnoSFB TR128
dc.identifier.issn2211-0348
dc.identifier.pubmed32674059
dc.identifier.scopus2-s2.0-85087787860
dc.identifier.urihttps://doi.org/10.1016/j.msard.2020.102376
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12711
dc.identifier.volume44
dc.identifier.wos000599869900013
dc.keywordsMyelin oligodendrocyte glycoprotein
dc.keywordsNeuromyelitis optica spectrum disorder
dc.keywordsOptic neuritis
dc.keywordsEncephalitis
dc.keywordsMagnetic resonance imaging
dc.language.isoeng
dc.publisherElsevier
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.openaccessN/A
dc.relation.projectOtoimmün Nörolojik Hastalıklarda İmmünopatogenezin ve Klinik Özelliklerle İlişkili Immünolojik Parametrelerin Araştırılması
dc.rightsN/A
dc.subjectClinical neuropsychology
dc.titleMyelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorVural, Atay
relation.isGoalOfPublicationa9786601-9431-4553-9a46-013bb366fb87
relation.isGoalOfPublication.latestForDiscoverya9786601-9431-4553-9a46-013bb366fb87
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isProjectOfPublicationacec34a8-1af9-438c-b703-e0b47154551a
relation.isProjectOfPublication.latestForDiscoveryacec34a8-1af9-438c-b703-e0b47154551a

Files